Categories: NewsPharmaceutical

Pacira to Report 2023 Financial Results on Thursday February 29, 2024

TAMPA, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2023 financial results before the open of the U.S. markets on Thursday February 29, 2024. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.

For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com. For those unable to participate in the live call, a replay of the webcast will be available on the Pacira website for approximately two weeks following the call.

About Pacira

Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

CONTACT: Investor Contact:

Pacira BioSciences, Inc.
Christian Pedetti, (973) 254-4387
Christian.Pedetti@pacira.com

Staff

Recent Posts

The Diabetes Research Institute, University of Miami, Announces Breakthrough Transplantation Approach for the Treatment of Type 1 Diabetes at ADA 2024

Novel Combination of Tolerance-Inducing Agent and Human Stem Cell-Derived Islets Demonstrates Functional Insulin Release and…

1 hour ago

GST/HST Removed for Counselling and Psychotherapy Services: A Significant Win for Mental Health in Canada

Ottawa, Ontario--(Newsfile Corp. - June 24, 2024) - The Canadian Counselling and Psychotherapy Association (CCPA)…

4 hours ago

Black-Owned Pharmacy Startup in St. Louis Combines Services of Walgreens and Amazon to Address Pharmacy Desert Crisis

ST. LOUIS, June 24, 2024 /PRNewswire/ -- St. Louis is home to the only Black-owned…

4 hours ago

World’s Largest Swimming Lesson™ (#WLSL2024) Kicks Off First Day of Summer with Global Event Teaching Kids and Parents How to Be Water Aware

More Than 600 Waterparks, Swim Schools and Pools in 19 Countries Taught an Estimated 43,000…

4 hours ago

Artificial Intelligence (AI) in Healthcare Market to Grow at 38.2% CAGR by 2031 | SkyQuest Technology

WESTFORD, Mass., June 24, 2024 /PRNewswire/ -- As per SkyQuest, the Global Artificial Intelligence in Healthcare Market…

4 hours ago

Thermal Cyclers Market Worth 1.86 Billion 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.

JERSEY CITY, N.J., June 24, 2024 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release…

4 hours ago